Drug Discovery World

NOVEMBER 16, 2022

DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . Therefore, while researchers can understand just how a drug molecule impacts a cell, they can’t be sure that it will perform the same when used in-vivo. .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

FEBRUARY 2, 2024

Every company does their purification differently, every company does their sequencing slightly differently, every company does their assays slightly differently. It’s not fully standardised, so companies still do some boutique work. However, we’re still a couple of years early for general purpose AI in science.

In-Vivo 52

In-Vivo Compliance Drugs Pharma Companies 52

Drug Discovery World

OCTOBER 4, 2022

The company’s candidate screening approach recapitulates aspects of tau oligomer formation in neurodegenerative diseases and enables the identification of novel therapeutic approaches. Several of the large pharma companies have recently re-entered the dementia field. Overcoming sector challenges . million in 2022 to 12.7

Development 52

Development In-Vivo Compound Screening Clinical Development 52

XTalks

AUGUST 17, 2020

To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

APRIL 3, 2023

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

World of DTC Marketing

JANUARY 31, 2021

I always have pointed instances in which pharma puts Wall Street first and patients second. Here are some of her key points from the report: 1ne: In just 10 years, the number of large, international pharmaceutical companies decreased six-fold,from60 to only 10. In pharma R&D returns have declined to 1.8 percent from 2018.

In-Vivo 187

In-Vivo Generic Drugs Gene Therapy Drugs 187

XTalks

DECEMBER 20, 2023

In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. This year, the very first CRISPR-based therapy received FDA approval for sickle cell disease.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Pharmaceutical Technology

MAY 24, 2023

Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. What are the general differences in the supply chain of CGT vs. traditional clinical trials? Differences in CGT vs traditional trials supply chain.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Drug Discovery World

JANUARY 24, 2024

Fibrocor is on track to complete all IND-enabling work to support IND filing and initiation of clinical trials in 2024. Phase I of the clinical program will dose healthy volunteers with single ascending doses of FIB992 before proceeding to a multiple ascending dose study where the drug is administered for a two-week period.

Research 59

Research Gene Expression Drugs Development 59

The Pharma Data

NOVEMBER 10, 2020

This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing. By giving companies full control of their studies, they are able to significantly speed up timelines,” Tessier said. Photo courtesy of Mispro.

Marketing 52

Marketing In-Vivo Scientist Research 52

Drug Discovery World

NOVEMBER 15, 2022

Developed with the idea of engineering an enzyme called terminal deoxynucleotidyl transferase (TdT), a type of DNA polymerase, these enzymatic DNA synthesis methods are now the focus of dozens of companies. Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

OCTOBER 1, 2020

To gain insight into the motivations, steps and experiences involved in an academia to industry — or vice versa — transition, Xtalks spoke to several leading scientists and entrepreneurs in pharma and biotech who successfully transitioned from academic positions to leadership roles in industry settings. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

OCTOBER 14, 2020

VBL has recently demonstrated ex-vivo activity of anti-MOSPD2 antibodies in patients with relapsing-remitting and progressive multiple sclerosis (MS), as well as in animal models of rheumatoid arthritis (RA), nonalcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD). 1. -- -->. -- [if lte IE 8]--> .

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

Pharmaceutical Technology

APRIL 12, 2023

In February, Massachusetts-based Charles River Laboratories, the second-largest importer of nonhuman primates into the US, was served a subpoena by the US Department of Justice regarding the company’s import of wild long-tailed macaques from Cambodia. This was part of an investigation into an international primate smuggling ring.

Regulation 245

Regulation Vaccination Vaccine Medicine 245